Literature DB >> 8312587

The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model.

D F Gibson1, D A Johnson, S M Langan-Fahey, M K Lababidi, W H Wolberg, V C Jordan.   

Abstract

The development of endometrial cancer is a potential risk during long-term tamoxifen therapy for breast cancer. In order to protect the uterus, progestin treatment has been proposed for these patients. However, within the 7,12-dimethylbenzanthracene-induced rat mammary model, progesterone is known to reverse the antitumor effects of tamoxifen. This study shows that progesterone administered intermittently still reverses the antitumor effects of tamoxifen in this model. This effect of progesterone is not due to a decrease in the tissue levels of tamoxifen, and may be direct, via the progesterone receptor.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8312587     DOI： 10.1007/bf00665699

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  24 in total

1.  Induction and extinction of mammary cancer. A striking effect of hydrocarbons permits analysis of mechanisms of causes and cure of breast cancer.

Authors:  C HUGGINS; N C YANG
Journal:  Science       Date:  1962-07-27       Impact factor: 47.728

2.  Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer.

Authors:  M Andersson; H H Storm; H T Mouridsen
Journal:  J Natl Cancer Inst       Date:  1991-07-17       Impact factor: 13.506

3.  Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model.

Authors:  S P Robinson; V C Jordan
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

4.  Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy.

Authors:  V C Jordan; M K Lababidi; S Langan-Fahey
Journal:  J Natl Cancer Inst       Date:  1991-04-03       Impact factor: 13.506

5.  Effects of clomiphene citrate and progesterone on resting and proliferative cell-populations in resting and proliferative cell-populations in mouse uterine epithelium.

Authors:  J Kimura; T Obata; H Okada
Journal:  Endocrinol Jpn       Date:  1976-10

6.  Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate.

Authors:  E Kordon; C Lanari; R Meiss; P Elizalde; E Charreau; C Dosne Pasqualini
Journal:  Breast Cancer Res Treat       Date:  1990-11       Impact factor: 4.872

7.  Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer.

Authors:  S M Langan-Fahey; D C Tormey; V C Jordan
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

8.  Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women.

Authors:  H T Mouridsen; K Ellemann; W Mattsson; T Palshof; J L Daehnfeldt; C Rose
Journal:  Cancer Treat Rep       Date:  1979-02

Review 9.  Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast.

Authors:  V C Jordan; M F Wolf; D M Mirecki; D A Whitford; W V Welshons
Journal:  Crit Rev Clin Lab Sci       Date:  1988       Impact factor: 6.250

10.  A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.

Authors:  T J Powles; J R Hardy; S E Ashley; G M Farrington; D Cosgrove; J B Davey; M Dowsett; J A McKinna; A G Nash; H D Sinnett
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640
View more
  1 in total

Review 1.  What do we know and what don't we know about tamoxifen in the human uterus.

Authors:  A Friedl; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.